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Intradermal (i.d.) and intramuscular (i.m.) injections when administered with or without electroporation
(EP) have the potential to tailor the immune response to DNA vaccination. This Phase I randomized
controlled clinical trial in human immunodeficiency virus type 1–negative volunteers investigated whe-
ther the site and mode of DNA vaccination influences the quality of induced cellular and humoral immune
responses following the DNA priming phase and subsequent protein boost with recombinant clade C CN54
gp140. A strategy of concurrent i.d. and i.m. DNA immunizations administered with or without EP was
adopted. Subtle differences were observed in the shaping of vaccine-induced virus-specific CD4+ and CD8+
T cell–mediated immune responses between groups receiving: i.d.EP + i.m., i.d. + i.m.EP, and i.d.EP + i.m.EP
regimens. The DNA priming phase induced 100% seroconversion in all of the groups. A single, non-
adjuvanted protein boost induced a rapid and profound increase in binding antibodies in all groups, with a
trend for higher responses in i.d.EP + i.m.EP. The magnitude of antigen-specific binding immunoglobulin G
correlated with neutralization of closely matched clade C 93MW965 virus and Fc-dimer receptor binding
(FccRIIa and FccRIIIa). These results offer new perspectives on the use of combined skin and muscle DNA
immunization in priming humoral and cellular responses to recombinant protein.
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INTRODUCTION
DNA-BASED VACCINATION is an attractive mode of
vaccine delivery, particularly against viral infec-
tions. DNA vaccines utilize the host for in vivo
biosynthesis of transgene products,1 hence imitat-
ing infectious pathways, and through host cell
post-translational modifications, the transgene
products more accurately represent the conforma-
tion of naturally expressed viral antigens.2 A lack
of anti-vector immunity provides the opportunity
for serial immunizations with multiple DNA de-
rived immunogens. DNA vaccination is typically
used as a component of heterologous prime-boost
strategies. In the context of generating humoral
responses, prime-boost vaccination is generally
thought to induce memory T-cell responses3 able to
boost subsequent T cell–dependent antibody re-
sponses to recombinant antigens.4 However, the
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extent to which DNA vaccination is able to prime
antigen-specific B cells directly, influencing their
antigen specificity, is less clear and likely depen-
dent on the intrinsic antigenicity of the vaccinating
immunogen. In this respect, the human immuno-
deficiency virus type 1 (HIV-1) envelope glycopro-
tein presents a particular challenge, known to be
poorly immunogenic due in part to the very high
density of glycans that restrict antibody recogni-
tion of the underlying protein.5,6 Indeed, with two
notable exceptions,7,8 the majority of clinical vac-
cine studies using injected naked plasmid DNA
encoding HIV-1 envelope glycoproteins have failed
to induce detectable antibody responses.9
Nevertheless, over recent years, the immuno-
genicity of DNA vaccines has been significantly
enhanced through the use of promoter selection
and codon optimization.1 Furthermore, the deliv-
ery of DNA in association with electroporation (EP)
has been shown to increase gene expression and
vaccine-induced responses dramatically.10–13 EP
generates an electric field at the vaccine site, cre-
ating temporary cell membrane instability, thereby
facilitating increased uptake of DNA. Importantly,
the inflammation associatedwith EP is also thought
to enhance antigen-presenting cell (APC) recruit-
ment.14,15 In recent Phase I HIV-1 prophylactic
vaccine trials, DNA vaccination with EP has been
shown to improve cell-mediated immunity (CMI),
while its impact on antibody induction wasminimal
or below the level of detection.16,17 The route of
vaccination is also thought to have profound effects
on prevailing immune responses. Most DNA vacci-
nations are delivered via the intramuscular (i.m.)
route.16 However, the low number of APC within
muscle tissues may be a rate-limiting factor in in-
ducing robust humoral responses.1,18,19 By contrast,
the skin has relatively high numbers of resident
APCable tomigrate to the draining lymphnodes via
lymphatic drainage where they preferentially in-
teract with CD4+ T follicular helper (Tfh) cells, in-
ducing naive B cells to make antibody.20 However,
the volumes that can be delivered via the intrader-
mal (i.d.) route are much smaller than can be de-
livered i.m., providing a practical constraint when
considering this route. Few clinical studies have
directly compared the performance of the two routes
for delivery of DNA, but preliminary data suggest
i.d. administration to be dose sparing and superior
with or without EP.21,22 These findings are sup-
ported by small-animal data, suggesting that
greater polyfunctional CD4+ T-cell responses are
seen after i.d. administration of aDNAvaccine, even
at 20% of the dose, when the same vaccine is ad-
ministered i.m.23 Furthermore, comparative studies
of i.d. and i.m. delivery followed by in vivo EP of SIV
Env DNA inmacaques suggested that i.d.EP induced
higher cross-reactiveantibody responses than i.m.EP,
while cell-mediated response induced by i.m.EP were
10-fold higher than those induced by i.d.EP.
24 The
predictive nature of these studies for human immu-
nogenicity is unclear.
This study sought to develop a DNA priming
strategy capable of reproducibly inducing detect-
able B-cell responses, evident before boosting with
recombinant protein. This has important relevance
to current multicomponent approaches for induc-
ing protective HIV-1 antibody responses, where a
series of immunogens maybe required to focus
humoral immune responses to recognize rarely
induced broadly neutralizing epitopes.6 Given the
high cost of recombinant protein manufacture, the
potential use of a series of DNA priming immuni-
zations prior to boosting of responses with a single
recombinant protein would provide an attractive
and cost-effective strategy for evaluating multi-
component vaccines.
It was hypothesized that combining the i.d. route,
which allows the vaccine to reach a site with a
plentiful and diverse number of APCs,25 with con-
current i.m. vaccination, which allows delivery of a
higher concentration of DNA, might result in en-
hanced immune responses to the in vivo-expressed
plasmid DNA vaccine transgenes. Previous pre-
clinical murine studies supported this hypothesis,
but the extent to which this would translate to hu-
man studies was unclear.26 More recently, in a hu-
man clinical study using a T cell–based vaccine, it
wasobserved that combined i.d. and i.m. vaccination
differentially impacted the quality of effector T-cell
functions.27 This study sought to optimize this reg-
imen to augment vaccine-induced humoral immu-
nity. As a first phase in developing this approach, a
single DNA plasmid vector expressing CN54 gp140
was used to deliverHIV-1 Env as a priming vaccine
immunogen.The impact ofEPon concurrent i.d. and
i.m. vaccinations to prime humoral and cellular re-
sponses was evaluated prior to boosting with a
model recombinant HIV-1 vaccine antigen, CN54-
gp140. The study deliberately did not use an adju-
vant for the protein boost in order to differentiate
clearly the impact of the different components of the
concurrent regimens. While humoral antibody re-
sponses were the principal focus of this study,
gp140-specific cellular responses were also evalu-
ated, as CD4 T-cell help is critical not only for the
development of cytotoxic CD8 responses but also for
the development of Env-specific functional antibody
responses. The results presented here demonstrate
that concurrent i.d./i.m. vaccination is a highly effec-
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tive activator of both cellular and humoral responses.
Of particular note is that the i.d.EP + i.m.EP combi-
nation generated both T- and B-cell responses that
were dramatically amplified by a homologous protein
boost in the absence of additional adjuvantation.
To the best of the authors’ knowledge, this is the
first clinical study to evaluate concurrent i.d./i.m.
plasmid DNA vaccination as part of a DNA prime-
protein boost strategy.
METHODS
Trial design
CUTHIVAC002 was a randomized, open label,
Phase IHIVvaccine trial in healthy volunteers aged
18–50 years. The target sample size was 24 partici-
pants who completed all immunizations. Partici-
pants were randomized into one of three methods
(i.d.EP + i.m., i.d. + i.m.EP, and i.d.EP + i.m.EP) of de-
livering DNA-C CN54ENV at weeks 0, 4, and 8 and
subsequently boostedwith recombinantCN54gp140
atweek20 (Fig. 1A).The randomizationmethodwas
block randomization using a computer-generated
algorithm, stratified on sex, and implemented
through the Cactus electronic data capture system
on theday of enrolment andfirst immunizationafter
confirmation of eligibility. Group 1 (i.d.EP + i.m.)
received i.d. immunization with EP combined with
i.m. immunization. Group 2 (i.d. + i.m.EP) received
i.d. immunization combinedwith i.m. immunization
with EP. Group 3 (i.d.EP + i.m.EP) received i.d. im-
munization with EP combined with i.m. immuniza-
tion with EP. Protein boosts were administered by
i.d. injection. Each volunteer was invited to attend
11 visits from screening through to 4weeks after the
final immunization, with anadditionalweek 44visit
to assess durability of induced humoral responses.
Those who did not complete the immunization
schedule were replaced without randomization.
Clinical trial authorization was granted by the
British Medicines and Healthcare products Reg-
ulatory Agency. Favorable ethical approval opinion
was given by the LondonRiversideResearchEthics
Committee, operating within the Research Ethics
Service of the British Health Research Authority.
The trial was registered with the European Union
Drug Regulating Authorities for Clinical Trials
(EudraCT) database and assigned the EudraCT
No. 2015-001023-23 and was registered with Clin-
icalTrials.gov under protocol ID NCT02589795
(date of registration October 28, 2015). The trial
was performed at theNIHRTrust Imperial Clinical
Research Facility, Hammersmith Hospital, Im-
perial College Healthcare NHS Trust (London,
United Kingdom).
Study participants and eligibility criteria
Healthy adults aged between 18 and 50 years at
low risk of HIV-1 infection and with no clinically
significant medical history or disorder that pre-
sented the potential for risk of influencing the re-
sults or impairing the participant’s ability to
participate in the study were enrolled. All partici-
pants provided written informed consent.
Interventions
Three different methods of delivering a DNA
vaccine (DNA-C CN54ENV) via combined i.m. and
i.d. routes with and without EP were explored, all
followed by a single recombinant HIV CN54gp140
administered by i.d. injection without EP. Staff
were trained in the injection and EP techniques as
part of the trial specific training.
DNA-C CN54ENV
The codon-optimizedplasmid (DNA-CCN54ENV)
encodes theHIV-1 cladeC gp140 (env) derived from
97CN54 and was manufactured in accordance with
Good Manufacturing Practice (GMP) by Ajinomoto
Althea Technologies (San Diego, CA). The plasmid
was formulated in phosphate-buffered saline
(PBS), pH 7.2, and supplied as a sterile solution for
injection.
Recombinant CN54 gp140
CN54gp140 is a recombinant gp140 derived from
the HIV-1 97CN54 Env coding sequence manu-
factured in accordance with GMP by Polymun
Scientific Immunbiologische Forschung GmbH
(Klosterneuburg, Austria). The protein comprises a
sequence of 670 amino acids and has previously
been shown to be immunogenic in humans.28,29 The
protein is heavily glycosylated and has a mass of
approximately 140kDa, as determined by sodium
dodecyl sulfate polyacrylamide gel electrophoresis
and size-exclusion chromatography. Furthermore,
the CN54gp140 secreted by CHO cells is oligo-
meric, and following purification is essentially tri-
meric, with a projected mass of 420kDa.
Intradermal DNA administration
DNA-C CN54ENV was administered in the ab-
sence of EP as a 1·0.15mL (0.6mg) i.d. injection via
a small needle (29 gauge), inserted into the dermis
overlying the deltoid muscle of the non-dominant
arm. An i.d. adapter (West Pharmaceutical Services,
Inc., Exton, PA) was used to facilitate the injection
and to ensure consistency of administration. The
‘‘bleb’’ or weal created was used as an indicator of
successful injection into the i.d. layer. Intradermal
DNA injectionwithEPwas administered via needle-
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Figure 1. (A) Trial schematic. Participants attendeda total of 12 visits,withDNA immunizations given atweek 0 (visit 2),week 4 (visit 4), andweek 8 (visit 6) followedby an
intradermal (i.d.) booster injectionof recombinantCN54gp140 atweek 20 (visit 8). Bloodwas taken fromparticipants at eachvisit, andmucosal sampleswere takenatweeks
0, 20, and 22 (visits 2, 8, and 10, respectively).Thick solid lines indicatean immunization visit (weeks 0, 4, 8, and 20).Dotted lines indicate a safety visit (weeks 1, 5, 9, 21, and 22).
Thin solid lines indicate a screenor follow-up visit (weeks 6, 24, and 44). (B)CONSORTflowdiagram. Participantswere randomized into oneof three groups. The numbers of
participants enrolled, randomized, followed up, and analyzed are shown for each treatment group. Color images available online at www.liebertpub.com/hum
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free jet injection (Medi-jector Vision; Antares Phar-
ma, EwingTownship,NJ)within thehandheldTDS-
ID integratedapplicator (TriGridDeliverySystem;
Ichor Medical Systems, San Diego, CA) as a 1·
0.15mL (0.6mg) injection into the dermis overlying
the deltoid muscle of the non-dominant arm. In-
tradermal administration was immediately followed
by the application of electrical stimulation. The elec-
trical field was applied at an amplitude of 330V/cm of
electrode spacing for a duration of 40ms, within a
400msinterval, resulting inbriefmusclecontractions.
Intramuscular DNA administration
DNA-C CN54ENV was administered as a
1 ·0.5mL (2mg) injection via a needle into the
vastus lateralis muscle of the upper thigh. For i.m.
DNA injection with EP, the disposable EP car-
tridge was loaded with the 1 ·0.5mL (2mg) DNA
vaccine and then adjusted to one of three depth
settings, corresponding to predefined ranges in
skin-fold thickness. The cartridge was loaded into
the EP device and applied to the vastus lateralis
muscle, followed immediately by the application of
electrical stimulation and brief muscle contrac-
tions (TriGrid Delivery System; Ichor Medical
Systems). The spacing of the TriGrid electrode
array was 6mm in a diamond-shaped configura-
tion, and the electrical field was applied at an am-
plitude of 250V/cm of electrode spacing for a 40ms
total duration applied as three pulses over a 400ms
interval, resulting in brief muscle contractions.
Intradermal protein boost injection
TheCN54gp140 vaccine (0.5mg/mL) as provided
by the manufacturer was administered as 1 ·
0.10mL (50 lg) injection, as described above for the
i.d. DNA injection without EP.
Objectives and primary endpoint measures
The main objective was to investigate the safety
and immunogenicity of the three different methods
of administering CN54ENV C clade DNA vaccine
(i.d.EP + i.m., i.d. + i.m.EP, and i.d.EP + i.m.EP) followed
by a single i.d. boost with recombinant CN54gp140
protein (Fig. 1A). The primary safety endpoint was a
Grade 3 or above solicited local, systemic, or labora-
tory adverse event, or any grade of other adverse
event leading to a clinical decision to discontinue
immunizations or with onset within 7 days of im-
munization. The primary immunogenicity endpoint
was the magnitude of antigen-specific systemic im-
munoglobulin G (IgG) antibody binding responses
(ng/mL) to CN54gp140 measured by binding
enzyme-linked immunosorbent assay (ELISA) using
serum collected 2weeks after the final immunization.
Reactogenicity and safety
Participants were monitored in the clinic for at
least 60min after each vaccination, and contacted by
telephone aday later. They completed diary cards for
7 days, and returned for review within 7 days when
they were asked about other adverse events and di-
ary cards were checked. The grade of solicited local
andsystemicadverseevents startingwithin7daysof
immunization, and other adverse events were re-
corded in the case record form and diary card and
entered in the study database for randomized par-
ticipants. Systemic safety was also assessed through
routine laboratory parameters (full blood count and
differential, renal, and liver biochemistry), and re-
ported in the electronic database. Adverse events
were graded using modified U.S. Food and Drug
Administration and Division of AIDS criteria.
Collection and processing
of mucosal secretions
Cervicovaginal secretions were collected from
female volunteers using an Instead Softcup, a
commercially available, self-inserted menstrual
cupmade of polyethylene. TheSoftcupwas inserted
into the upper vagina, left in place for at least 1h,
removed, and stored in a 50mL Falcon tube at
-80C. Mucosal samples were collected at weeks 0,
20, and 22. Prior to processing the mucosal sam-
ples, the Softcups containing cervicovaginal secre-
tions were removed from storage at -80C and
thawed overnight at 2–8C. Following centrifuga-
tion at 400 g for 15min at 4C, an equal volume of
extraction buffer (1 ·protease inhibitor cocktail;
Calbiochem, San Diego, CA), 0.02% NaN3 (Sigma–
Aldrich, St. Louis, MO), and 0.25M NaCl (BDH) in
sterile PBS (Gibco, Waltham, MA)) was added to
the secretion samples (1:1 dilution). Samples were
then aliquoted and stored at -80C until analysis.
Rectal secretions were collected using a PVA
sponge, pre-moistened with 50lL saline and stored
at -80C. Sponges were removed from storage at
-80C, thawed on wet ice, and placed into a 50mL
tube containing a sterile 70lm Falcon filter unit.
Extraction buffer (500lL) was added before centri-
fugationat400g for 10minat4C.To removedebris,
the eluate was transferred into the top chamber of a
Spin–X tube, centrifuged at 16,000g for 15min at
4C, aliquoted, and stored at -80C until analysis.
Peripheral blood mononuclear cell
sample preparation
Peripheral blood mononuclear cells (PBMC)
were isolated using density gradient separation
fromheparinizedwhole blood. Cells were processed
within 4h of collection and stored at 1·107 cells/mL
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in freezing media (10% dimethyl sulfoxide, 90%
fetal bovine serum; Sigma–Aldrich) at -80C be-
fore storage in vapor phase liquid nitrogen prior to
analysis.
Memory B-cell enzyme-linked immunospot
B-cell enzyme-linked immunospot (ELISpot)
was used to assess the magnitude of CN54gp140
antigen-specific memory B cells (mBC) responses.
In brief, frozen PBMC were thawed and re-
suspended at 1 ·106 cells/mL in stimulation media
composed of 5ng/mL interleukin (IL)-2 (Roche,
Welwyn Garden City, United Kingdom) and 0.5lg/
mL R848 (Invivogen, San Diego, CA) before being
cultured for 4 days at 37C, 5%CO2. Sterile 96-well
ELISpot plates (Millipore, Billerica, MA) were pre-
wet with 15lL/well 70% EtOH for 1min before
washing with Dulbecco’s PBS. Wells were coated
overnight at 4C with 5lg/mL CN54gp140-antigen,
15lg/mL of the capture antibody MT91/145 (Mab-
tech, Stockholm, Sweden), or PBS only. Plates were
blocked with RPMI supplemented with 10% heat-
inactivated fetal calf serum (FCS; R10) for 1–2h
before the addition of 10,000 cells/well for total IgG
and 200,000 cells/well for antigen-specific re-
sponses. Each conditionwas tested in triplicate, and
plates were incubated for 6h at 37C, 5% CO2.
Biotinylated detection antibody MT78/145 (Mab-
tech) was added at 1lg/mL in PBS/0.5% FCS and
incubated overnight at 4C. The next day,
streptavidin-horseradish peroxidase (HRP; Mab-
tech) diluted 1:1000 in PBS/0.5% FCS was added
and incubated for 1h at room temperature. AEC
substrate solution (BD Biosciences, San Diego,
CA) was added and incubated for 5–10min before
stopping the spot development with tap water.
Spot-forming units (SFU) were counted using
an automated AID ELISpot reader (Autoimmun
Diagnostika GmbH, Straßberg, Germany).
Interferon gamma ELISpot
Interferon gamma (IFN-c) ELISpot assays were
performed using frozen isolated PBMC stimulated
with peptide pools matched to the vaccine at sam-
pling weeks, 0, 20 and 22. In brief, frozen PBMC
were rested overnight at a concentration of 2.5·106
PBMC/mL and re-suspended to a final concentra-
tion of 4·106 viable PBMC/mL (4·105 PBMC/mL
for positive control phytohemagglutinin [PHA]
wells). Pre-coated IFN-c ELISpot 96-well plates
(Mabtech) were washed with sterile PBS and
blocked with R10media before the addition of 50lL
cells/well in triplicate with 50lL media only, stim-
ulation media containing vaccine-specific peptide
pools Env 1, 2, and 3 (15-mers overlapping by 11
covering the entire sequence of CN54gp140 clas C
HIV-1) and two positive controls PHA; Sigma–
Aldrich; and cytomegalovirus/Epstein Barr virus/
influenza virus/tetanus [CEFT]; (thinkpeptides,
Oxford, United Kingdom) at a final concentration of
2.5lg/mL. Plates were incubated for 16–24h at
37C, 5% CO2. Plates were then washed and incu-
bated for 2h at room temperature with 1lg/mL
mouse-anti human IFN-c (Mabtech). The signalwas
amplified with 1h incubation with streptavidin-
ALP solution (Mabtech), then developed with sub-
strate, 5-bromo-4-chloro-3¢-indolyphosphate and
nitro-blue tetrazolium (BCIP/NBT plus; Mabtech)
for 5–7min. The reaction was stopped by washing
with tap water and allowed to dry overnight in the
dark. Plates were read with an automated AID
iSPOT ELISpot plate reader (Autoimmun Diag-
nostikaGmbH). The number of SFU/106 PBMCwas
calculated as the mean count subtracting the back-
ground count. Pass/fail criteria for the assay was
dependent on the mean of the negative wells <100
SFU/106 PBMC, and thePHA-positive responsewas
>500 SFU/106 PBMC.
Intracellular cytokine analysis
T-cell responses were evaluated by intracellular
cytokine staining (ICS) with a panel for CD8+ and
CD4+ antigen-specific responses. In brief, cryo-
preserved PBMC were thawed and rested over-
night in R10 media at 37C, 5% CO2. 1 ·106 viable
PBMC were stimulated with 2.5lg/mL of each
vaccine-matched peptide pools (Env 1, 2, and 3)
plus 1lg/mL CD28/49d (BD Biosciences) for 6h at
37C. Phorbol 12-myristate 13-acetate/ionomycin
(Sigma–Aldrich), and CEFT were used as positive
controls and R10media with 1.5%DMSOwas used
as a negative control. Two hours into the stimula-
tion, Brefeldin A (eBioscience, San Diego, CA) was
added. Cells were stained with fixable viability
dye eFluor780 (eBioscience), CD3 BV650 (Clone
OKT3), CD4 PerCP-Cy5.5 (RPA-T4), CD8 AF700
(RPA-T8), IFN-c AF488 (4S.B3), TNF-a PE-Cy7
(MAb11), IL-2 BV510 (MQ1-17H12), CD154 BV421
(24–31) (BioLegend, San Diego, CA), Granzyme B
AF647 (GB11; BD Biosciences), and Perforin PE
(dG9; eBioscienceCA) to assess CD4/CD8-specific
responses. Cells were fixed and stored at 2–8C be-
fore analysis on aFortessaLSRII (BectonDickinson,
Franklin Lakes, NJ) equipped with 50mW 405nm,
50mW 488nm, 50mW 561nm, and 20mW 633nm
lasers and a ND1.0 filter in front of the FSC photo-
diode. Acquisition was set to record 50,000 live
CD3+ lymphocytes after dead cell and doublet ex-
clusion (FSC-A/W, SSC-A/W gating). Analysis was
performed using FlowJo v10 software (Treestar,
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Ashland, OR), PESTLE and SPICE software (cour-
tesy of Mario Roederer, Vaccine Research Center,
National Institutes of Allergy and Infectious Dis-
eases). Data were expressed as the percentage of
total CD4+ or CD8+ cells. Background responses in
negative controls were subtracted from the stimu-
lated samples. Responders were defined as having
three times the background and a percentage
staining >0.05% after subtraction of the baseline
(prior to vaccination) result.
HIV-specific binding antibodies
Antigen-specific gp140 binding antibodies were
measured using standardized ELISA platforms. In
serum samples, antigen-specific IgA, IgG, and IgG
subclasses were measured. In brief, 96-well high
binding plates (Griener, Kremsmu¨nster, Austria)
were coated with recombinant CN54gp140 (Poly-
mun Scientific) at 1 lg/mL in PBS for 1h. As ref-
erence material, standard immunoglobulins
(Sigma–Aldrich) were captured with anti-human
kappa and lambda light chain specific mouse an-
tibodies (Southern Biotech, Birmingham, AL).
After blocking with assay buffer (1% bovine serum
albumin; Sigma–Aldrich; 0.05% Tween Thermo
Fisher Scientific, Pittsburgh, PA), samples were
initially screened at 1:100 dilution (then titrated to
optimal dilutions) on antigen-coated wells, and
serial dilutions of immunoglobulin standards were
added to the kappa/lambda capture antibody
coated wells and incubated for 1 h at 37C. Sec-
ondary antibody HRP-conjugated anti-human IgG
was added at 1:20,000 dilution and incubated for
1 h at 37C. Plates were developed with SureBlue
TMB substrate (KPL, Insight Biotechnology, Lon-
don, United Kingdom). The reaction was stopped
after 5min by adding TMB stop solution (KPL,
Insight Biotechnology), and the absorbance was
read at 450nm on a VersaMax 96-well microplate
reader (Molecular Devices, Sunnyvale, CA). The
ELISA data are expressed as positive if the blank-
subtractedOD450nmwas above the predetermined
cutoff of OD 0.2nm and values are on the linear
range of the curve. To ensure assay sensitivity, a
positive control composed of positive pooled plasma
samples was used. Analyses of the data were per-
formed using SoftMax Pro GxP software v6.5
(Molecular Devices).
IgG subclasses 1–4 were investigated for serum
samples only. The protocol was followed as above
with the use of IgG1–4 standards (Abcam, Cam-
bridge, United Kingdom and Sigma–Aldrich) and
mouse anti-human IgG1 HRP (Acris, Rockville,
MD), mouse anti-human IgG3 HRP (Southern Bio-
tech), or mouse anti-human IgG4 HRP (BD Bios-
ciences). The IgG2 assay included a mouse anti-
human IgG2-biotin (BD Biosciences) step followed
by 1:200 streptavidin-HRP (RD Systems, Minnea-
polis, MN), as previously described.28
Antigen-specific IgA/G antibody responses were
measured in the mucosal compartments (vaginal
and rectal) at weeks 0, 20, and 22 using a super-
sensitive polyHRP ELISA. In addition, any serum
samples determined to be below the limit of quan-
tification in the conventional ELISA were retested
using this assay. In brief, 96-well high binding
plates (Nunc, Roskilde, Denmark) were coated
overnight with antigen and capture antibody (as
above) at 4C. Casein buffer (Thermo Fisher Sci-
entific, Waltham, MA) was used to block plates
before addition of mucosal samples and standards
(serially diluted 1:10) for 1h at 37C. Secondary
antibody, biotin-conjugated anti-human IgG
(Southern Biotech) was added and incubated for
1 h at 37C before addition of streptavidin poly-
HRP40 (Fitzgerald, Acton, MA) for 40min at room
temperature. Plates were developed and read as
detailed for the conventional ELISA.
Customized multiplex dimer assay
A customized multivariate multiplex assay was
developed using a panel of gp140 antigens (Clade
C: CN54, 1086; Clade A: UG37; Clade B: 9021,
JRFL; Clade D: UG21; Clade F BR29 and M con-
sensus NIH AIDS Reagents) coupled to magnetic
fluorescentmultiplex beads (Bio-Rad), as described
previously.30 Biotinylated dimeric Fc-gamma-
Receptors (FccRIIa-H131, FccRIIIa-V158) were
produced as previously described,31 and kindly sup-
plied by Drs. Bruce Wines and Mark Hogarth, Bur-
net Institute (Melbourne, Australia).
Coupled microspheres were premixed in multi-
plex assay buffer (PBS +0.1% BSA +0.05% Tween),
creating a working mixture of 12.5 microspheres/
bead type/lL. Using a black, clear-bottom 96-well
plate, 40 lL of the working microsphere mixture
(1,000 beads of each type/well) was added to 40 lL
of 100 · diluted serum (diluted in PBS). The plate
was covered and incubated overnight at 4C on a
plate shaker. The plate was washed three times
with 200 lL of assay wash (PBS-1 · , 0.1% BSA,
0.5% Triton-100 · ) using a Bio-Plex Pro plate
wash station (Bio-Rad). Antigen-specific anti-
body binding to dimeric FccRs was detected by
adding FccRs followed by streptavidin PE at
1.0 lg/mL with 50 lg/well. After 2 h incubation
at room temperature on a shaker, the plate was
washed three times with 200 lL of assay wash,
and microspheres were re-suspended in 100 lL of
sheath fluid.
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A Bio-Plex reader (Bio-Plex MAGPIX, Bio-Plex
Manager 5.0; Bio-Rad) was used to detect the mi-
crospheres, and binding of PE was measured to
calculate a median fluorescence intensity (MFI).
Background signal, defined as the average MFI
observed for each microsphere set when incubated
with the PE-conjugated detection reagent in the
absence of clinical antibody sample, was subtracted
from the MFI for each sample.
HIV-1 neutralization assay
Env-pseudotyped viruses (PSV) SF162 and
MNec.3 (subtype B), 93MW965.26 (subtype C), and
TH023.06 (CRF01-AE) were produced in HEK293T
cells, titered, and used inTZM-bl assay to determine
neutralizing antibody responses.32 Briefly, dupli-
cates of six steps of threefold dilution, starting with
1:20 of each serum obtained at weeks 0 and 22, were
incubated with viral supernatant (at relative lumi-
nescence units [RLU] between 148,000 and 272,000)
for 1h. Thereafter, 104 TZM-bl cellswere added, and
plates were incubated for 48h, when luciferase ac-
tivity was measured by addition of Bright-Glo Lu-
ciferase assay system (Promega, Madison, WI).
Neutralization titers were defined as the sample
dilution at which RLU were reduced by 50% com-
pared to virus control wells after subtraction of
background RLU in control wells with only cells.
Statistical methods
The primary safety outcome was expressed as a
proportion of participants with 95% confidence in-
terval, and groups were compared using Fisher’s
exact test. There was no pre-specified hypothesis on
which to power the study. Immunological analyses
were based on the per protocol (PP) population that
received all vaccinations. All immunology data were
performed observer blinded by use of a randomly
generated laboratory identifier. Appropriate com-
parative statistics are annotated in the text. For the
immunogenicity analysis, the primary end point
was defined as 2 weeks after the fourth and final
vaccine (week 20). Statistical analysis was carried
out using Prism v7.04 (GraphPad Software, Inc.,
San Diego, CA) or R v3.3.2 (R Foundation, Vienna,
Austria).
RESULTS
Concurrent i.d. and i.m. DNA vaccination
with and without EP and protein boost
schedule was well tolerated in healthy
HIV-negative adult volunteers
Study volunteers were recruited between Au-
gust 2016 and February 2017. Twenty-eight were
screened during the randomized period, with 24
deemed eligible and enrolled (Supplementary
Table S1; Supplementary Data are available online
at www.liebertpub.com/hum). Two participants
(i.d.EP + i.m.EP) withdrew consent, and one (i.d.EP +
i.m.) was lost to follow-up during the immunization
period. The TDS-ID device failed to deliver the first
dose of vaccine in a fourth participant (CV024B)
included in i.d.EP + i.m.EP (Fig. 1B). Seven volun-
teers were screened and four additional eligible
participants enrolled to replace the individuals
who did not complete their immunizations, mat-
ched on sex but not age. One (i.d.EP + i.m.) of the
four replacement participants did not receive the
CN54gp140 boost because, for personal reasons, he
wished to minimize the longevity of vaccine-
induced seroreactivity in HIV tests. A total of 28
volunteers received 103 of 112 planned doses of
vaccines between August 30, 2016, and July 17,
2017, and 23 completed the immunization sched-
ule. The majority of randomized participants were
white British (71%) and male (75%) with a mean
age of 27 years. The four participants recruited to
replace those who did not complete their immuni-
zations were similar, with a mean age of 33 years
(Supplementary Tables S2 and S3).
All participants attended the safety visit within
a week of their last immunization, and 25 attended
the final safety visit at week 24. There were no
adverse events that resulted in a clinical decision to
discontinue vaccines among randomized and non-
randomized participants. There was one serious
adverse event: a road traffic accident that occurred
5 months after the last vaccine. There were two
severe (grade 3) solicited events reported by ran-
domized participants: arm discomfort after the
third vaccination (i.d.EP + i.m.) and elevated as-
partate transaminase after the first vaccination
(i.d. + i.m.EP). One of the non-randomized individ-
uals (i.d.EP + i.m.EP) reported two events after her
third immunization: severe tiredness and severe
general muscle aches. There were 23 non-solicited
adverse events with onset within 7 days of immu-
nization reported by randomized participants and
two by non-randomized participants; these were
mainlymusculoskeletal or infection, and they were
mild or moderate in severity.
Of the 365 events reported by the randomized
participants, which includes the primary outcomes
described above, 342 (94%) were solicited local,
systemic, or laboratory events, 335 (92%) were
mild, and 263 (72%) local to the injection site
(Supplementary Table S4). The most common ad-
verse events were discomfort and redness in the
arm, discomfort in the leg, and blistering at the site
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of i.d. injection. Of 57 blistering events, 15 were
moderate in grade, making this the commonest
moderate adverse event observed in all groups,
most frequent after the last immunization (Sup-
plementary Tables S5 and S6).
Concurrent i.d. and i.m. DNA vaccination
with EP enhances antibody response
to HIV-1 gp140 pre- and post-boosting
with recombinant protein
Antibody responses were determined 1 week
post final DNA vaccination (week 9). All individu-
als in i.d.EP + i.m. (group1) seroconverted post third
DNA vaccination (8/8; 100%). In i.d. + i.m.EP (group
2), 6/8 (75%) seroconverted by week 9, rising to 8/8
(100%) at the timeof protein immunization. In i.d.EP+
i.m.EP, 8/9 (88.8%) individuals seroconverted by
week 9, with an additional seroconversion detected
on the day of protein boost (group 3; Fig. 2A–C). This
late responder (CV024B) was the one participant
where the TDS-ID device failed to deliver the first
i.d. doses of the vaccine. Interestingly, for the ma-
jority of individuals across the groups, antibody re-
sponses continued to rise between weeks 9 and 20
(19/25; 76%). mBC ELISpot responses were concor-
dant with seroconversion. Although there was no
statistical difference between groups in the median
antibody binding response atweek 9 post thirdDNA
immunization, mBC responses were higher in i.d.EP
+ i.m.EP (group 3) relative to i.d.EP + i.m. (group 1;
Fig. 2E; p=0.041). Nevertheless, all groups had
similar mBC responses on protein boosting.
Following protein boost, participants from i.d.EP+
i.m. (group 1) had a median antibody response of
13,934ng/mL (Q1–Q3: 9,884–38,050ng/mL; Fig. 2A
andD) at 2weeks (week 22) post protein vaccination
(primary endpoint). For the participants followed
out toweek 44, this dropped to 2,751ng/mL (Q1–Q3:
461–13,225ng/mL). One participant in this group
chose not to receive a protein boost (CV910U) but
was followed out to study end, where the antibody
responses had returned to baseline. A median re-
sponse of 11,292ng/mL (Q1–Q3: 9,608–15,568ng/
mL) 2 weeks post protein boost was seen in i.d. +
i.m.EP (group 2). For those participants followed out
to week 44, this fell to 3,012ng/mL (Q1–Q3: 1,425–
3,720 ng/mL; Fig. 2B and D). The median anti-
body response at 2 weeks post boost in i.d.EP +
i.m.EP (group3) was 31,418ng/mL (Q1–Q3: 6,304–
128,259ng/mL). For those participants in group 3
followed out to week 44, the median antibody re-
sponse fell to 1,444ng/mL (Q1–Q3: 476–20,634ng/
mL; Fig. 2C andD).When assessed by group, i.d.EP +
i.m.EP (group 3) displayed a trend for earlier re-
sponses to the protein boost and elevated peak an-
tibody response at the primary endpoint (week 22)
when compared to groups 1 and 2 (Fig. 2A–C).
However, this was not statistically significant. Post
protein boost, mBC responses were seen in all in-
dividuals, except for the one individual in group 1
who declined their protein boost. Although there
was no statistical difference between the three
groups, the highest mean response was in i.d.EP +
i.m.EP (group 3).
To understand the functionality of the induced
response further, the induced antibody isotype
profile was then determined. There was a pre-
dominant IgG1 response, with some sporadic in-
duction of IgG2 and IgA (Fig. 2F). Interestingly,
IgG3 responses, although low, were most repro-
ducibly observed in groups 2 and 3 (7/8 and 8/9,
respectively) while less frequent for group 1 (4/8).
Subsequently, differences in the ability of vaccine-
induced serum antibodies to interact with dimeric
Fc receptors FccRIIIa and/or FccRIIa after binding
to various HIV-1 clade Env proteins were investi-
gated as an indirect readout for potential antibody
dependent cellular cytotoxicity (ADCC) and anti-
body dependent cellular phagocytosis (ADCP).30,31
Env-specific antibodies with capacity to bind FcR
dimers were induced by the different prime-boost
vaccine regimens. Overall, the fingerprint of Fc-
receptor binding, associated with different HIV-1
clades, was similar in pattern across the three
groups. However, there was a trend for higher
median response for both Env-specific FccRIIIa
and FccRIIa binding antibodies in i.d.EP + i.m.EP
(group 3; Fig. 2G andH). In all groups, homologous,
group M consensus, clade C, F, and D binding
vaccine-induced antibodies were detected by the
dimeric FccRIIIa and FccRIIa, while vaccine-
induced antibodies specific to clade B were low or
absent, and clade A did not bind to dimeric
FccRIIIa and FccRIIa. Low levels of neutralizing
antibody were observed at week 22 against the
closely matched clade C tier 1 isolate 93MW965, in
line with previous observations using this envelope
construct28,29,33 (Fig. 2I).
Cervical and rectal mucosal IgG and IgA specific
antibody levels were also determined 2 weeks
(week 22) post protein vaccination (primary end-
point). No rectal IgA was detected in any of the
participants, with rectal IgG being detected at low
levels in only one participant from group 1 and
group 3 (35ng/mL and 52ng/mL, respectively).
Each of the vaccination groups contained two
females. Therefore, cervical antibodies were de-
termined for these participants. Cervical IgA was
not detected in women from group 2 or group 3,
with one participant in group 1 showing negligible
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Figure 2. Antigen-specific humoral responses in human serum samples following DNA prime-protein boost vaccination regimens. Participants received
3· priming immunizations of DNA-C CN54ENV at weeks 0, 4, and 8 by (A) i.d.EP + i.m. (orange), (B) i.d. + i.m.EP (light blue), and (C) i.d.EP + i.m.EP (gray)
administration, followed by a common i.d. booster injection of recombinant CN54gp140 at week 20. Individual responses are shown in (A–C) and median
responses in (D). Percentage of Ag-specific memory B cells (mBC) per total immunoglobulin G (IgG)-secreting mBC as shown in (E) following DNA priming
(week 20) and protein boost (week 22). mBC responses were significantly higher in i.d.EP + i.m.EP (group 3) relative to i.d.EP + i.m. at week 20 ( p = 0.041).
CN54gp140-specific IgG1-4 and IgA responses expressed as median are shown in (F). The ability of vaccine-induced antibodies isolated at week 22
recognizing different HIV gp140 proteins to bind dimeric (G) FccRIIIa or (H) FccRIIa was assessed in a customized multiplex dimer assay. Serum neutralizing
antibody titers, analyzed by TZM-bl assay (I), data expressed as ID50 against a variety of viruses at week 22, 2 weeks after the protein boost. Statistical
analysis was performed using a Kruskal–Wallis test with Dunn’s correction for multiple comparisons. i.d.EP + i.m., received i.d. immunization with electro-
poration (EP) combined with intramuscular (i.m.) immunization; i.d. + i.m.EP, received i.d. immunization combined with i.m. immunization with EP; i.d.EP + i.m.EP,
received i.d. immunization with EP combined with i.m. immunization with EP. i.m., intramuscular. Color images available online at www.liebertpub.com/hum
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antibody levels of 13ng/mL. Cervical IgG re-
sponses were detected in all women, irrespective of
vaccination scheme, with median values of 104ng/
mL (group 1), 57ng/mL (group 2), and 1,871ng/mL
(group 3; Supplementary Fig. S1).
EP modulates the response profile of induced
CD4 T cells in response to concurrent i.d.
and i.m. DNA vaccination prior to boosting
with recombinant protein
Next, the response profile of the induced CD4
cellular immune response was assessed by ICS as a
marker of CD4 T-cell help. Analysis of the total
number of responders to any of the measured pa-
rameters following DNA vaccination (week 20) re-
vealed a nonsignificant trend for fewer responders
(5/8; 62.5%) in i.d.EP + i.m. (group 1) compared to
7/8 (87.5%) in i.d. + i.m.EP (group 2), and 7/9 (77.8%)
in i.d.EP+ i.m.EP (group 3). This trend was not
changed upon protein boosting (week 22), whereby
there were 4/8 (50%) responders in i.d.EP + i.m.
(group 1) compared to 6/8 (75%) in i.d. + i.m.EP
(group 2), and 7/9 (77.8%) in i.d.EP + i.m.EP (group
3). When analyzing the profile of responding CD4
T-cell populations following DNA vaccination
(Fig. 3A), the magnitude of the induced TNF-a re-
sponsewas lower in i.d.EP + i.m. (group 1) compared
to i.d. + i.m.EP (group 2; p= 0.048, chop-lump
test34). Responses in i.d.EP + i.m.EP (group3) across
all four markers (CD154, IFN-c, TNF-a, and IL-2)
were greater in magnitude than either i.d.EP + i.m.
(group 1) or i.d. + i.m.EP (group 2) following DNA
vaccination, although this did not reach statistical
significance, except for TNF-a responses that were
greater than those in group 1 (group 3; p=0.041,
chop-lump test). Furthermore, there was a trend for
i.d.EP + i.m.EP (group 3) to have a higher fraction of
polyfunctional cells expressing all four markers
(Fig. 3C) compared to the other two groups. There
was little change in the response rate and overall
response profile following protein boost. However,
there was a trend for increased TNF-a and INF-c
expression in i.d.EP + i.m.EP (group3; Fig. 3B) and
higher levels of polyfunctionality (‡3 parameters)
relative to the other two groups (Fig. 3D). Con-
versely, levels of single CD154-positive cells were
increased in i.d.EP + i.m. (group 2) relative to groups
1 and 3 (Fig. 3D).
CD8 T-cell responses are also differentially
modulated by concurrent i.d. and i.m. DNA
vaccination prior to boosting
While the primary focus of this study was on
factors influencing humoral responses, to assess
the wider implications of concurrent i.d. and i.m.
DNA vaccination, the study also sought to deter-
mine the impact on CD8 responses. ICS analysis
of the total number of CD8+ T-cell responders
following DNA vaccination (week 20) revealed
higher numbers in the two groups receiving i.d.
EP, where i.d.EP + i.m. (group 1) and i.d.EP + i.m.EP
(group 3) had 6/8 (75%) and 6/9 (66.7%) respond-
ers, respectively, while there were only two (25%)
responders in i.d. + i.m.EP (group 2) who did not
receive i.d. EP. The protein boost did not change
the number of responders in i.d.EP + i.m.EP (group
3), but there was a reduction the number of re-
sponders in i.d.EP + i.m. (group 1; from 6/8 to 4/8),
while an additional responder was seen in i.d. +
i.m.EP (group 2; 3/8 [37.5%]). Analysis of the induced
response profile in the responding CD8 cells fol-
lowing DNA vaccination revealed an inherent bias
toward CD154 responses in the two groups receiv-
ing i.d.EP (groups 1 and 3) relative to the two re-
sponders in i.d. + i.m.EP (group 2; Fig. 4A). Boosting
with recombinant gp140 shifted the response in i.d.
+ i.m.EP (group 2) toward a more CD154 dominated
profile (Fig. 4B andD)with stronger IL-2 responses.
Unlike CD4 T-cell responses, polyfunctional analy-
sis revealed that the greatest proportion of CD8 T
cells responding post DNA vaccination were single
positive, with very few of the cells showing high
poly-functionality associated with expression of
three or four of the markers (Fig. 4C). As expected
for exogenous protein immunogens, there was little
change in the response profile following the boost
(Fig. 4D).
EP modulates IFN-c T-cell ELISpot responses
in healthy volunteers receiving concurrent i.d.
and i.m. DNA vaccination prior to boosting
with recombinant protein
To facilitate comparison across vaccine studies,
the differential impact of the individual DNA im-
munization schedules on the induced cellular re-
sponses was also assessed by IFN-c T-cell ELISpot.
Positive IFN-c responses 12 weeks post third DNA
vaccination (week 20) were seen in 2/8 (25%) par-
ticipants who received i.d.EP + i.m. (group 1), 4/8
(50%) who received i.d. + i.m.EP (group 2), and 5/9
(55.6%) who received i.d.EP + i.m.EP (group 3) vac-
cination (Fig. 5A). While there was no statistical
difference in the number of responders between
groups (chi-square test), the difference in magni-
tude of the IFN-c response was statistically signif-
icant between i.d.EP + i.m.EP (group 3) and i.d.EP +
i.m. (group 1; p=0.001). Within i.d.EP + i.m.EP,
the greatest magnitude of IFN-c response was to
peptide pools 1 and 2, withmean values of 238 SFU/
106 PBMC (95% CI 0–480 SFU/106 PBMC) and 227
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SFU/106 PBMC (95%CI 18–437 SFU/106 PBMC) at
week 20, respectively (Supplementary Fig. S2C).
The subsequent protein boost was associated with a
marginal change in response rate at the primary
endpoint (week 22, 2 weeks following protein boost),
where i.d.EP + i.m. (group 1) dropped to 1/8 (12.5%)
participants and i.d.EP + i.m. (group 2) and i.d.EP +
i.m.EP (group 3) increased to 5/8 (62.5%) and 6/9
(66.7%), respectively (Fig. 5A). There was a statis-
tically significant difference between i.d.EP + i.m.EP
(group 3) and i.d. + i.m.EP (group 1; p=0.002). Sta-
tistical differences in the magnitude of response
across all peptide pools when compared to back-
ground were observed for i.d. + i.m.EP (group 2) and
i.d.EP + i.m.EP (group 3) but not for i.d.EP + i.m.
(group 1; Supplementary Fig. S2A–C).
A similar trend was observed when IFN-c re-
sponseswereassessed by ICS,with thehierarchy in
thenumber of respondersbeing i.d.EP+ i.m.EP> i.d.+
i.m.EP > i.d.EP + i.m. Positive CD4 IFN-c responses
followingDNAvaccination (week 20) were seen in 3/
8 (37.5%) participants who received i.d.EP + i.m.
(group 1), 4/8 (50%) who received i.d. + i.m.EP (group
2), and 7/9 (77.8%) who received i.d.EP + i.m.EP
(group 3) vaccination (Fig. 5B). Subsequent to the
protein boost, response rates decreased for i.d.EP +
i.m. (group 1) to 0/8, remained constant for i.d. +
i.m.EP (group 2), and decreased for i.d.EP + i.m.EP
(group 3) to 6/9 (66.7%; week 22). Differences in the
magnitude of the CD4 T-cell IFN-c response by ICS
were significant between i.d.EP + i.m.EP (group 3)
and i.d.EP + i.m. (group 1) post protein boost
(p=0.006). There were fewer positive CD8 IFN-c
responses compared to CD4 responses, although
interestingly thesewere lowest in i.d.+ i.m.EP (group
2), suggestive of an association with i.d.EP and the
induction of CD8 IFN-c responses (Fig. 5C).
Antibody functionality correlates
to the magnitude of antigen-specific IgG
but not CMI, regardless of vaccine regime
Finally, the data were analyzed to determine
any association between the magnitude of binding
antibody and any of the measured response pa-
rameters. There was no correlation between the
magnitude of specific IgG and any of the cellular
responses at week 22, both gamma interferon
ELISpot or CD4/CD8 ICS (Supplementary Fig. S3).
As anticipated, there was a strong correlation be-
tween total antigen-specific IgG and the predomi-
nant antigen-specific IgG1 response (r =0.89) but
no correlation with other isotypes. The magnitude
of antigen-specific binding IgG also correlated with
neutralization titer (r= 0.77 for 93MW965) and Fc-
dimer receptor binding (FccRIIa and FccRIIIa;
Supplementary Figures 3 and 4).
DISCUSSION
This study sought to develop a DNA priming
strategy capable of reproducibly inducing detect-
able B-cell responses, evident before boosting with
recombinant protein. The rationale behind this
approach was to select conditions that would fa-
cilitate the use of DNA vaccines to evaluate a broad
range of immunogens used in series or as a cocktail
to focus humoral immune responses to recognize
rarely induced broadly neutralizing epitopes6 prior
to amplification with a conventional recombinant
protein boost. However, while the ability of DNA to
prime CD4 T-cell responses is well established, the
extent to which DNA vaccination is able to prime
antigen specific B cells directly is less clear. Indeed,
a review of previous HIV vaccines studies per-
formed by the HIV vaccine Trials Network sug-
gests that antibody responses are rarely elicited by
DNA priming in the absence of EP.9
To the best of the authors’ knowledge, this is the
first human study to determine the impact of DNA
priming vaccination by combined i.d. and i.m. ad-
ministration followed by i.d. boosting with recom-
binant protein. In general, the different modes of
delivery (i.d.EP + i.m., i.d. + i.m.EP, and i.d.EP +
i.m.EP) were well tolerated, with no serious adverse
events reported during the trial. Encouragingly,
100% seroconversion was seen prior to the protein
boost across all three DNA priming regimes. Al-
‰
Figure 3. Intracellular cytokine staining (ICS) CD4 T-cell analysis. Baseline percentages have been subtracted from the week 20 and week 22 (primary
endpoint) values (A–D). Radar plots (A and B) demonstrate the mean T-cell response for each vaccination group according to cytokine expression levels as a
marker of function following (A) DNA priming (week 20) and (B) protein boost (week 22). Pie charts compare the average functionalities of CD4+ T cells
according to the three groups following DNA priming (C) and protein boost (D). Polyfunctionality was defined as the concurrent expression of three or more
functions. Pie slices denote proportions of CD4+ T cells co-expressing four (red), three (yellow), two (green), and one function (blue). Pie arcs represent
proportions of the CD4+ T-cell response expressing CD154 (light blue arcs), interferon (IFN)-c (purple arcs), interleukin (IL)-2 (red arcs), and tumor necrosis
factor (TNF)-a (light green arcs). Bar graphs depict concurrent expression of CD154, IFN-c, IL-2, and TNF-a within CD4+ T cells following stimulation with CN54
peptides. The x-axis represents positive (+) and negative (–) responses within each combination of CD154, IFN-c, IL-2, and TNF-a functional subset. The y-axis
represents the percentage of antigen-specific CD4+ T cells contributing a given functional subset. Bars indicate mean values. Statistical analysis was
performed using a Kruskal–Wallis test with Dunn’s correction for multiple comparisons. Color images available online at www.liebertpub.com/hum
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though there was no statistical difference in the
median binding antibodies, the highest mBC re-
sponses were observed in i.d.EP + i.m.EP. Further-
more, following the protein boost, i.d.EP + i.m.EP
(group 3) displayed a trend for earlier responses and
elevated peak antibody responses at the primary
endpoint compared to groups 1 and 2. Larger stud-
ies will be needed to determine if these differences
are statistically significant. It should be noted that
i.d. and i.m. immunizations were administered to
different limbs (arm and leg respectively) that drain
to different lymph nodes. Whether this anatomical
separation of the two injections is necessary for the
observed effects warrants further study. The dose of
DNA delivered i.d. was also considerably lower
(600lg) than the i.m. dose (2mg). Therefore, it
cannot be excluded that administration of two con-
current i.d./EP doses might be equivalent or greater
than that of combined i.d./EP + i.m./EP with respect
to antibody priming. A further limitation of this
study is the lack of a control group that did not re-
ceive EP by either route of administration. How-
ever, previous studies showing the strong impact of
EP on induced responses suggest this would have
been inferior.10–16 There are no directly comparable
human studies investigating combined i.d. + i.m.
immunization to either i.d. or i.m. administered in
the context of EP. The closest matched study is that
of Vasan et al.16 comparing i.m. administration of
DNA-based candidate HIV-1 vaccine expressing
Clade C/B¢ env, gag, pol, nef, and tat genes with and
without EP delivered by the same device as used in
this study. In this previous study, only one partici-
pant displayed a transient very weak antibody re-
sponse to gp120. A second study exploring the use of
ID DNA administration for a multivalent vaccine
encoding Env, Gag, Pol, with and without EP using
a different device (Dermavax), failed to show any
benefit fromEPandno evidence of seroconversion to
the DNA priming phase.17
However, the responses to multigenic vaccines
are likely to be different to those encoding a single
HIV-1 Env sequence. A parallel ongoing study
(DNAVAC) using the same DNA vaccine has failed
to produce significant seroconversion following
three immunizations with either i.d.EP or i.m.EP
(pers. commun.). These data suggest that combined
i.d. and i.m. immunization in the context of EP is
superior to either i.d. or i.m. immunization alone.
It should be noted that two previous clinical
studies have reported seroconversion to HIV-1
envelope following DNA priming in the absence of
EP. The first of these assessed responses following
three injections of a six-plasmid HIV-1 DNA vac-
cine encoding gp145 of subtype A, B, C, and Env
and subtype BGag, Pol, andNef administered by a
needle-free Biojector2000.7 This study reported a
71% seroconversion rate, with a median antibody
titer of 800 to Env (A, C, B). Although the Biojector
administration was targeted to the lateral deltoid
muscle, the ballistic nature of administration
likely distributed DNA across both dermal and
muscle tissue. A second study utilized a six-
plasmid HIV-1 DNA vaccine encoding codon-
optimized gp120 Env from subtypes, A, B( · 2), C,
and E, and a subtype C Gag.8 When administered
at a high dose (7.2mg at each immunization) via
i.m. injection divided between two sites in the
absence of EP, 4/6 (66.7%) volunteers showed de-
tectable Env-specific IgG, with median binding
titers of 1,600. The higher dose, greater intrinsic
immunogenicity of gp120 monomers over trimeric
gp140, and differences in expression plasmids
likely account for higher seroconversion rates
when compared to other studies. It is certainly
possible that this latter study did not involve the
use of EP and might also be effective for priming
responses to subsequent protein boost. Never-
theless, neither of these two previous studies was
able to match the 100% seroconversion following
the combined i.d./i.m. DNA priming observed in
this study. Further work is required to determine
whether such a difference provides significant
justification for the more complicated delivery pro-
cedure. Interestingly, a prototype device for simul-
taneous EP-enhanced DNA vaccine delivery to both
skin and muscle is under development, offering the
potential to simplify the approach.35
‰
Figure 4. ICS CD8 T-cell analysis. Baseline percentages have been subtracted from the week 20 and week 22 (primary endpoint) values (A–D). Radar plots
(A and B) demonstrate the mean T-cell response for each vaccination group according to cytokine expression levels as a marker of function following (A)
DNA priming (week 20) and (B) protein boost (week 22). Pie charts compare the average functionalities of CD8+ T cells according to the three groups following
DNA priming (C) and protein boost (D). Polyfunctionality was defined as the concurrent expression of three or more functions. Pie slices denote proportions of
CD8+ T cells co-expressing four (red), three (yellow), two (green), and one function (blue). Pie arcs represent proportions of the CD8+ T-cell response
expressing CD154 (light blue arcs), IFN-c (purple arcs), IL-2 (red arcs), and TNF-a (light green arcs). Bar graphs depict concurrent expression of CD154, IFN-c,
IL-2, and TNF-a within CD8+ T cells following stimulation with CN54 peptides. The x-axis represents positive (+) and negative (–) responses within each
combination of CD154, IFN-c, IL-2, and TNF-a functional subset. The y-axis represents the percentage of antigen-specific CD8+ T cells contributing a given
functional subset. Bars indicate mean values. Statistical analysis was performed using a Kruskal–Wallis Test with Dunn’s correction for multiple comparisons.
Color images available online at www.liebertpub.com/hum
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In the current study, the magnitude of induced
humoral responses following a single i.d. boostwith
recombinant CN54 gp140 in the absence of ad-
juvant was similar to that previously observed
following two immunizations with the same re-
combinant protein (CN54 gp140) delivered with
the TLR adjuvant GLA-AF28 or following different
DNA-MVA priming regimes.33 The different DNA
prime-protein boost regimes in this study induced a
predominant IgG1 response with lower levels of
IgG3. IgG2 responses were less evident than in
previous studies using recombinant CN54 gp140
adjuvanted in GLA-AF,28 suggesting the DNA
priming phase promoted a more Th1 dominant re-
sponse. In line with previous studies CN54 gp140
induced low neutralizing antibody responses
against a closely matched clade C tier 1 isolate
MW965 with minimal reactivity against clade B
MN and SF162 and clade A/E recombinant
TH023.28,29,33 However, vaccine-induced serum
antibodies were seen to interact with dimeric Fc
receptors FccRIIIa and/or FccRIIa, surrogates of
both ADCC and ADCP, respectively.30,31 In par-
ticular clade C, F, and D binding vaccine-induced
antibodies were detected by the dimeric FccRIIIa
and FccRIIa. Similar to the neutralization profile,
vaccine-induced antibodies specific to clade A and
B were either absent or too low to crosslink dimeric
FccRIIIa and FccRIIa. These responses mirror
previous observations seen when using recombi-
nant protein alone.28 The potential importance of
ADCC has been highlighted by the RV144 trial in
which robust HIV-specific ADCC responses were
linked to the observed partial protection.36–38
Data using the CN54 gp140 Env suggest potential
ADCC and/or ADCP would be restricted to clades
C, F, and D.
Intramuscular EP appeared to have a positive
impact on the response frequency of Env-specific
CD4 responses elicited after three DNA immuni-
zations with i.d. + i.m.EP and i.d.EP + i.m.EP,
showing 97.5% and 77.8% responses, respectively,
compared to 62.5% for i.d.EP + i.m. Although not
statistically relevant, this positive association fits
earlier observations that i.m.EP preferentially in-
duces CD4 T-cell responses.16 Furthermore, CD4
responses in i.d.EP + i.m.EP across all four markers
(CD154, IFN-c, TNF-a, and IL-2) were greater in
magnitude and had a higher fraction of polyfunc-
tional cells (‡3markers) than the other two groups.
By contrast, i.d.EP appeared to have a positive im-
pact on the response frequency of Env-specific CD8
responses, where i.d.EP + i.m. and i.d.EP + i.m.EP
had 75% and 66.7% response rates, respectively,
compared to 25% in i.d. + i.m.EP group. Preferential
induction of CD8 T cells responses by DNA vacci-
nation of the skin concords with previous clinical
studies using a T cell-based DNA vaccine.27 Inter-
estingly, when response rate was determined by
IFN-cT-cell ELISpot, often assumed to be amarker
of CTL response, hierarchy in the number of re-
sponders was i.d.EP + i.m.EP > i.d. + i.m.EP > i.d.EP +
i.m., more reflective of CD4 T-cell responses.
However, further analysis by ICS demonstrated a
predominance of IFN-c-positive CD4 T cells rela-
tive to CD8 T cells. This is in line with previous
studies by Vasan et al. showing a predominant
IFN-c CD4 T-cell response following i.m.EP
16 that
were of a similar magnitude and frequency.
Correlation analysis failed to show an associa-
tion between any of the measured cell-mediated
response parameters and themagnitude of binding
antibody. These data suggest that the measured
cellular parameters have no impact on the magni-
Figure 5. T-cell IFN-c enzyme-linked immunospot responses following DNA priming (week 20) and protein boost (week 22), the primary endpoint (A). All
responses expressed as spot-forming units (SFU) per million peripheral blood mononuclear cells (PBMC), with background subtracted (SFU/106 PBMC). Mean
values –95% confidence intervals are shown. Shading represents responses to the three peptide pools (PP). Antigen-specific CD4 (B) and CD8 (C) T cells
producing IFN-c at week 20 and week 22 as measured by ICS. The boxes show the median– interquartile ranges and min/max values. Statistical analysis was
performed using a Kruskal–Wallis Test with Dunn’s correction for multiple comparisons. Color images available online at www.liebertpub.com/hum
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tude of induced antibody and are not predictive
of lymph node Tfh responses required to provide
B-cell help. Future studies will be required to assess
the induction of better biomarkers of Tfh responses
in the systemic compartment and/or responding
lymph nodes.39 Unsurprisingly, there was a strong
correlation between total antigen-specific IgG and
antigen-specific IgG1 responses (r=0.89), with IgG1
being the predominant isotype response. The
magnitude of antigen-specific binding IgG also
correlated with neutralization titer (r= 0.77 for
93MW965) and Fc-dimer receptor binding (FccRIIa
and FccRIIIa; Supplementary Fig. S4). Stronger
correlations with FccRIIa compared to FccIIIa
likely reflect the observed subclass distribution of
IgG1, 2, and 3 levels. IgG1 and IgG3 bind well to
both FccRIIa and IIIa, while IgG2 only binds well
to FccRIIa.
Collectively, the data presented here support
the concept for the use of concurrent i.d. and i.m.
DNA priming vaccination combinations as medi-
ators of robust T- and B-cell responses, with pro-
tein boost immunizations serving to amplify
antibody levels efficiently. The study objective of
identifying a DNA priming strategy capable of
reproducibly inducing detectable antibody re-
sponses in the majority of subjects was met. While
the three DNA priming strategies each induced
100% seroconversion, i.d.EP + i.m.EP performed
best. Interestingly, responses for the majority of
the participants were maintained or increased
over the 12 weeks following the third DNA vacci-
nation and the time of the protein boost. It would
be interesting to know if additional concurrent
DNA immunizationmight provide further gains in
antibody titer. Molecular adjuvants were not used
in order to differentiate clearly the impacts of the
different components of the concurrent regimens.
However, additional gains might be mediated by
the future inclusion of molecular adjuvants in the
DNA-priming phase with potential impact on
avidity and neutralization breadth. In the current
phase of development, a single DNA plasmid was
used as a proof-of-concept study. The studies
clearly demonstrate that the combined i.d.EP +
i.m.EP protocol is capable of directly priming
antigen-specific B cells. In future studies, it will be
important to determine whether a series of DNA
immunogens and/or combinations can drive B-cell
responses toward rarely induced broadly neutral-
izing antibodies, with their potential amplification
with a single protein boost. Such an approach has
obvious attractions, given the relative savings in
speed and cost of DNA manufacture compared
to other vaccine platforms. In this respect, the
DNA prime-protein boost approach has potential
not only to accelerate the testing of candidate
HIV-1 vaccines with the aim of elucidating im-
munogens capable of inducing broadly neutraliz-
ing antibody responses, but also to provide a new
platform for the development of future vaccines
against a wide range of existing or emerging
pathogens.
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